Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987539) titled 'A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)' on May 16.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Amgen
Condition:
Generalized Myasthenia Gravis
Intervention:
Drug: Inebilizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 29, 2025
Target Sample Size: 15
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06987539
Discl...